Floatz logo

VITPSO

Advanced Solid Tumor Cancer

Immunolight, LLCSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Advanced Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
lm-24c5
LaNova Medicines Limited
Phase 2CCC
Shr-A1811
Sheng Zhang
Phase 2CCC
Capecitabine
National University Hospital, Singapore
Phase 1/2CCC
gh55
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2CC
bnt3214
BioNTech SE
Phase 1/2CC

View all 19 →

Same molecule, other indications

VITPSO is also rated in:

mycosis fungoidesDormant
BB
Indicative ·
67 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
67 / 100
View asset →
Metastatic Pancreatic AdenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →